Document is current

Any future updates will be listed below

Can Kisqali® (Ribociclib) effectively target triple-negative breast cancer? A computational insight on potential mechanisms and therapeutic strategies

Crossref DOI link: https://doi.org/10.1007/s44371-025-00161-8

Published Online: 2025-05-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark